Rutgers-Affiliated Start-Up Company Receives Funding for Technology to Help Choose Breast Cancer Treatments

The National Institutes of Health (NIH) has awarded a Rutgers-affiliated company (Ibris, Inc.) $207,000 to develop a quick and economical analysis of tissue from breast cancer biopsies. The technology is designed to predict how aggressive a common form of breast cancer is likely to be, helping physicians and patients plan effective therapies that minimize side effects.

 

Ibris, Inc. was formed in 2010 by Madabhushi and James Monaco, an assistant research professor in Madabhushi’s lab. Scott Doyle, who earned his doctorate under Madabhushi in April of 2011, recently joined the company as vice president of research. Ganesan is serving as the clinical principal investigator from the University of Medicine and Dentistry of New Jersey. Doctoral student Ajay Basavanhally contributed to Ibris technology development. Pathologists Michael Feldman and John Tomaszewski from the Hospital of the University of Pennsylvania have helped with data and annotations.

Madabhushi credits the Rutgers Office of Technology Commercialization for assistance in licensing the technology and creating Ibris, Inc. He also credits the university’s Center for Innovative Ventures of Emerging Technologies (CIVET) for helping to arrange early-stage funding for the start-up company and business plan assistance from the Rutgers Business School.

 

Click Here for the full article.